Methoxsalen    (DrugBank: Methoxsalen)

3 diseases
IDDisease name (Link within this page)Number of trials
36Epidermolysis bullosa1
46Malignant rheumatoid arthritis2
96Crohn disease3

36. Epidermolysis bullosa    [ 147 clinical trials,   170 drugs,   (DrugBank: 40 drugs),   32 drug target genes,   113 drug target pathways]
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 147 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00004359
(ClinicalTrials.gov)
February 199618/10/1999Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa AcquisitaEpidermolysis Bullosa AcquisitaDrug: methoxsalenNational Center for Research Resources (NCRR)Northwestern UniversityCompleted18 YearsN/ABoth10Phase 2NULL

46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 4,183 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-001825-69-IT
(EUCTR)
04/11/200514/12/2005A Multi Center, Open label, Extension study of RA 1 using Extracoproreal photoimmune therapy with UvadexA Multi Center, Open label, Extension study of RA 1 using Extracoproreal photoimmune therapy with Uvadex Rheumatoid arthritis
MedDRA version: 6.1;Level: PT;Classification code 10039073
Trade Name: UVADEX
INN or Proposed INN: Methoxsalen
THERAKOSNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
68Italy
2NCT00221000
(ClinicalTrials.gov)
August 200313/9/2005Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid ArthritisA Phase II, Multicenter, Randomized, Double-blind, Sham Pheresis-controlled, Study of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis in Patients Who Have an Inadequate Response to Disease Modifying Antirheumatic Drugs and Biological AgentsRheumatoid ArthritisDrug: Methoxsalen;Procedure: Extracorporeal PhotopheresisMallinckrodtNULLCompleted18 YearsN/ABoth86Phase 2United States;Australia;Austria;Belgium;Canada;France;Germany;Italy;Mexico;Slovakia;South Africa

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 2,209 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-002693-37-DE
(EUCTR)
14/03/200506/01/2005A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSANTS AND/OR ANTI-TNF AGENTS - CD-2A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSANTS AND/OR ANTI-TNF AGENTS - CD-2 Patients with Moderately Active Crohn’s Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
MedDRA version: 7.1;Level: LLT;Classification code 10011401
Trade Name: UVADEX
INN or Proposed INN: methoxsalen
TherakosNULLNot RecruitingFemale: yes
Male: yes
25Germany
2EUCTR2004-002693-37-AT
(EUCTR)
10/12/200405/11/2004A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSANTS AND/OR ANTI-TNF AGENTS - N/AA MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSANTS AND/OR ANTI-TNF AGENTS - N/A Patients with Moderately Active Crohn’s Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
MedDRA version: 7.1;Level: LLT;Classification code 10011401
Trade Name: UVADEX
INN or Proposed INN: methoxsalen
TherakosNULLNot RecruitingFemale: yes
Male: yes
25Austria;Germany
3NCT00221026
(ClinicalTrials.gov)
December 200413/9/2005Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's DiseaseA Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF AgentsCrohn's DiseaseDrug: Methoxsalen +ECP;Procedure: Extracorporeal PhotopheresisMallinckrodtICON plcCompleted18 YearsN/ABoth25Phase 2United States;Austria;Belgium;Germany